secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-162763
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049
--------------------------------------------------------------------------------

- SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.
- SALT≤30 at wk52: 30.2% low, 35.0% high vs 8.4% placebo (p=0.023). SALT50: 37.7% low, 38.8% high vs 13.6% placebo.
- 94% of 31 patients completed 16-week extension; no discontinuations due to TEAEs. Injection site reactions mild-to-moderate, self-resolving within 5 days.
- Nektar will submit results to a medical conference in 2026 and plans to advance rezpegaldesleukin into registrational trials in alopecia areata.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312526162763/0001193125-26-162763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312526162763/d25375d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-162763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer